Bridging Rare Disease Innovation - from East to West, from Lab to Life.

Kos Biotechnology Partners makes a strategic investment in Golden Age Health

Golden Age Health welcomes Kos Biotechnology Partners as an investor, through its fund Kos BioVentures. Alex Tzoukas, Co-Founder and Managing Partner of Kos, will join our Board of Directors. The investment supports the expansion of GAH's commercial platform and partner portfolio in Greater China and Asia-Pacific.

Golden Age Health supports the 2026 LHON Patient Summit in Guangzhou

China's annual LHON patient gathering, organized by CORD and the Leber Youth patient community, met in Guangzhou on 6 September with support from Golden Age Health as a non-promotional educational initiative.

100 LHON patients treated with Raxone in seven months in Hainan

On 28 August the 100th patient received Raxone at Ruijin Hainan Hospital. Patients have come from 26 provinces, municipalities and autonomous regions of China, and from Japan and Myanmar.

Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.

Leadership delegation visits Jinan, Shandong

Michel Vounatsos, Yossi BenAmram and Chao (Brook) Wu met the Mayor of Jinan and leaders of the Jinan Innovation Zone, Jinan Hi-Tech Holding Group and Qilu Pharmaceutical, joined by partner Innostellar, to build a two-way bridge between global and Chinese innovation.

First international LHON patients treated with Raxone in Hainan

On 14 July two patients from Japan and Myanmar were treated at Ruijin Hainan Hospital, the first international LHON patients treated in the Boao Lecheng International Medical Tourism Pilot Zone.

Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.

Golden Age Health expands into Taiwan and appoints Jeremy Lin as General Manager

Jeremy Lin brings more than 20 years of leadership at Roche, MSD, Sanofi and Novartis, and will build Golden Age Health Taiwan to expand access to rare disease and specialty therapies.

National Eye Care Day: more than 80 LHON patients treated with Raxone in Hainan

On China's 31st National Eye Care Day, more than 80 patients living with LHON had received Raxone through the early access program of the Boao Lecheng International Medical Tourism Pilot Zone at Ruijin Hainan Hospital.

Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.

Welltech Ventures announces its investment in Golden Age Health

Welltech Ventures welcomed Golden Age Health to its portfolio.

More than 50 LHON patients in China have received Raxone

Through the Boao Lecheng International Medical Tourism Pilot Zone's early access policy, more than 50 LHON patients received Raxone by the end of March.

Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.

Commercialization agreement for ZTALMY signed with Tenacia

Golden Age Health and Tenacia Biopharmaceuticals signed the commercialization agreement for ZTALMY, the first and only approved treatment for CDKL5 deficiency disorder in mainland China.

Rare Disease Day 2026

On Rare Disease Day, Golden Age Health stands with the more than 300 million people worldwide living with a rare disease.

Tenacia Biopharmaceuticals and Golden Age Health partner to commercialize ZTALMY in mainland China

Golden Age Health (Shanghai) receives exclusive rights to commercialize ZTALMY, the first approved treatment in mainland China for seizures associated with CDKL5 deficiency disorder.